8 completed, 3 recruiting, 1 active not recruiting, 1 suspended. 15 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 8, Recruiting 3, Active not recruiting 1, Suspended 1, Terminated 1, Unknown 1 |
| Phase 2 | 6 | Completed 3, Recruiting 2, Active not recruiting 1 |
Follow Recurrent Osteosarcoma: new trials by email Literature Review of Recurrent Osteosarcoma trials Research Report on Recurrent Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine - Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-01-16 | 2026-09-01 |
| IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma IM83 CAR-T Cells - Refractory Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 9 | 2024-06-15 | 2024-05-14 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 73 | 2022-01-25 | 2026-11-12 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Docetaxel, Gemcitabine, Hydroxychloroquine - Recurrent Osteosarcoma, Refractory Osteosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2019-01-28 | 2026-11-10 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-06-05 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors tanespimycin, pharmacological study, laboratory biomarker analysis - Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 70 | 2004-09-01 | 2013-06-04 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 95 | 2004-02-01 | 2013-06-05 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas alvocidib, pharmacological study - Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2001-04-01 | 2013-07-02 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma tanespimycin, pharmacological study - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 1999-10-01 | 2013-02-07 |
Osteosarcoma (15) · Neuroblastoma (9) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Wilms Tumor (4) · Astrocytoma (3) · Burkitt Lymphoma (3) · Familial ependymoma (3) · Lymphoma, Non-Hodgkin (3) · Medulloblastoma (3) · Melanoma (3) · Recurrence (3) · Rhabdomyosarcoma (3) · Sarcoma (3) · Chondrosarcoma (2) · Dendritic Cell Sarcoma, Interdigitating (2)
Neoplasms by Histologic Type (15) · Neoplasms, Bone Tissue (15) · Neoplasms, Connective Tissue (15) · Neoplasms, Connective and Soft Tissue (15) · Neoplasms (14) · Sarcoma (12) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Nerve Tissue (11) · Neoplasms, Neuroepithelial (11) · Neuroectodermal Tumors (11) · Neuroectodermal Tumors, Primitive (11) · Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6)
Biopsy (3) · Specimen Handling (3) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Temozolomide (2) · X-Rays (2) · tanespimycin (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Absorptiometry, Photon (1) · Bone Density (1) · CTLA-4 Antigen (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · HhAntag691 (1)
National Cancer Institute (NCI) (9) · Children's Oncology Group (2) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (14) · Canada (3) · China (1)
Crystal L Mackall (1) · Emily G Greengard (1) · James Whitlock (1) · John A Livingston (1) · Lisa McGregor (1) · Michelle Choe, MD (1) · Mrinal Gounder (1) · Ramesh Ramanathan (1) · Regina Jakacki (1) · Robbie G Majzner (1) · Rosandra N Kaplan (1) · Sara Federico, MD (1) · Sarah B Whittle (1) · Tanya Trippett (1) · Yu Zhang, PhD (1)
PMID 31401903, PMID 32192573, PMID 38520670
U01CA097452 (3), UM1CA228823 (3), U01CA069856 (2), UM1CA097452 (2), N01CM62206 (1), P30CA008748 (1), P30CA015704 (1), U01CA099168 (1), U01CA154967 (1), U24CA224309 (1), UM1CA154967 (1)